

HR 2283

CHANGE Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 10, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 11, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2283>

Sponsor

Name: Rep. Sánchez, Linda T. [D-CA-38]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (47 total)

Cosponsor	Party / State	Role	Date Joined
Rep. LaHood, Darin [R-IL-18]	R · IL		Apr 10, 2019
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Apr 10, 2019
Rep. McMorris Rodgers, Cathy [R-WA-5]	R · WA		Apr 10, 2019
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		May 9, 2019
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		May 9, 2019
Rep. Higgins, Brian [D-NY-26]	D · NY		May 9, 2019
Rep. Kuster, Ann M. [D-NH-2]	D · NH		May 9, 2019
Rep. Waters, Maxine [D-CA-43]	D · CA		May 9, 2019
Rep. Smith, Christopher H. [R-NJ-4]	R · NJ		May 21, 2019
Rep. Mast, Brian J. [R-FL-18]	R · FL		Jun 5, 2019
Rep. DelBene, Suzan K. [D-WA-1]	D · WA		Jun 10, 2019
Rep. Pocan, Mark [D-WI-2]	D · WI		Jun 18, 2019
Rep. Stevens, Haley M. [D-MI-11]	D · MI		Jun 18, 2019
Rep. Lowenthal, Alan S. [D-CA-47]	D · CA		Jun 25, 2019
Rep. Scott, David [D-GA-13]	D · GA		Jun 27, 2019
Rep. Lieu, Ted [D-CA-33]	D · CA		Jul 16, 2019
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Jul 16, 2019
Rep. Roybal-Allard, Lucille [D-CA-40]	D · CA		Aug 2, 2019
Rep. Demings, Val Butler [D-FL-10]	D · FL		Sep 6, 2019
Rep. Khanna, Ro [D-CA-17]	D · CA		Sep 6, 2019
Rep. Posey, Bill [R-FL-8]	R · FL		Sep 6, 2019
Rep. Grothman, Glenn [R-WI-6]	R · WI		Sep 19, 2019
Rep. Cole, Tom [R-OK-4]	R · OK		Oct 21, 2019
Rep. Kennedy, Joseph P., III [D-MA-4]	D · MA		Oct 21, 2019
Rep. Sires, Albio [D-NJ-8]	D · NJ		Oct 21, 2019
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Oct 28, 2019
Rep. Lamb, Conor [D-PA-17]	D · PA		Oct 28, 2019
Rep. Payne, Donald M., Jr. [D-NJ-10]	D · NJ		Oct 28, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Oct 28, 2019
Rep. Lewis, John [D-GA-5]	D · GA		Oct 31, 2019
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Nov 12, 2019
Rep. Lofgren, Zoe [D-CA-19]	D · CA		Nov 12, 2019
Rep. Upton, Fred [R-MI-6]	R · MI		Nov 12, 2019
Rep. Rice, Kathleen M. [D-NY-4]	D · NY		Nov 21, 2019
Rep. Chu, Judy [D-CA-27]	D · CA		Dec 9, 2019
Rep. Doyle, Michael F. [D-PA-18]	D · PA		Dec 9, 2019
Rep. Gomez, Jimmy [D-CA-34]	D · CA		Dec 17, 2019
Rep. Suozzi, Thomas R. [D-NY-3]	D · NY		Dec 17, 2019
Rep. Takano, Mark [D-CA-41]	D · CA		Dec 17, 2019
Rep. Stanton, Greg [D-AZ-9]	D · AZ		Dec 19, 2019
Rep. McGovern, James P. [D-MA-2]	D · MA		Jan 9, 2020

Cosponsor	Party / State	Role	Date Joined
Rep. Smith, Jason [R-MO-8]	R · MO		Jan 30, 2020
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jan 30, 2020
Rep. Kinzinger, Adam [R-IL-16]	R · IL		Feb 11, 2020
Rep. Lee, Susie [D-NV-3]	D · NV		Mar 5, 2020
Rep. Sherrill, Mikie [D-NJ-11]	D · NJ		Aug 11, 2020
Rep. Beatty, Joyce [D-OH-3]	D · OH		Aug 25, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 11, 2019
Ways and Means Committee	House	Referred To	Apr 10, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 1126	Related bill	Apr 10, 2019: Read twice and referred to the Committee on Finance.

Summary (as of Apr 10, 2019)

Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2019 or the CHANGE Act of 2019

This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports.

Additionally, the Centers for Medicare and Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices.

The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.

Actions Timeline

- **Apr 11, 2019:** Referred to the Subcommittee on Health.
- **Apr 10, 2019:** Introduced in House
- **Apr 10, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.